Pharmaceutical industry across the globe bench marks the standard of regulatory processes carried out by Food and Drug Administration of USA (USFDA). India which has th e highest number of USFDA approved plants outside of USA itself, has been confronted with slew of warning letters and import alerts from the said regulatory authority, which especially were accentuated during last six years i.e. from FY13-FY18. The current article delineates upon analysis on classification of violations cited by FDA for Indian Pharma cos, inputs provided by them while concluding with solutions to overcome majority of the regulatory observations.
With market size of around $ 35 bn in FY2018, Indian pharmaceutical industry is ranked third globally in terms of volume and thirteenth in terms of value. Indian pharmaceutical companies, over decades of arduous efforts, have gradually developed the necessary technology, capacities and capabilities to meet the demand and to explore the opportunities provided by global regulated markets; and currently, United States of America (USA) contributes about one third of the total Indian pharmaceutical exports. Furthermore, Indian pharmaceutical manufacturing companies accounted for 36% of the total Abbreviated New Drug Application (ANDA) approvals by USA in 2017 as compared with 34% in 2016; the total number of ANDA approvals has increased from 201 to 304 during the same period. India has second highest number of USFDA (United States Food and Drug Administration) approved manufacturing plants, ie, about 700 units with over 5000 ANDA approved drug products during last decade i.e. 2008-2017.
With all the aforesaid accolades, however, lately, it has been noted that there has been a spurt in the issuance of the import alerts and warning letters for domestic manufacturing facilities significantly over the past years following USFDA’s increasing focus on compliance of guidelines of cGMP. This restricts the manufacturing units to supply drugs to the US market from that facility resulting in the decline of revenue for the companies particularly to US market and also from other markets subsequently if the issues are not closed out to the earliest.
Sequence observed by USFDA in regulatory enforcement:
This story is from the September 2018 edition of Pharma Bio World.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the September 2018 edition of Pharma Bio World.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Can Indian Traditional Medicinal Systems Show The Way Forward?
Indian traditional codified medicinal systems and folk medicine are a vast lexicon of herbal formulations and medicinal plants. In last few decades, the popularity of herbal medicine/ products has increased worldwide, not only as part of conventional treatment strategies but also for health care management, and thus the opportunity to promote Indian traditional medicine is increasing globally. Recently people from several developed and developing countries have been attracted toward traditional Indian herbal medicines. A large number of modern medicines are derived from the plants used in Ayurveda and other traditional medicinal systems. Ayurveda and other traditional herbal medicines are capable of addressing some modern unmet medical needs, and can provide the basis for developing potential medicines. Lack of drug standardization, information, quality control, and strict monitoring are the primary lacunae in the promotion of traditional Indian herbal products. In recent years several regulatory and promotional approaches have been undertaken to overcome such problems. Quality control, rigorous research to establish the effectiveness and safety, and credible clinical trials of the herbal products are required. Thus, the careful and scientific integration of Indian traditional herbal medicine into evidence-based clinical management of diseases is essential to provide better health care facilities to people.
Only About 5% Of Rare Diseases Have Treatments
Orphan drugs, those medications that are typically produced in small quantities for limited patient populations, are growing in importance worldwide.
Sustainability In Processing And Packaging Technology; Technological Solutions For Ecological Challenges
The article analyses current ways of the pharma industry to make for more sustainable packaging and manufacturing processes, from utilising biodegradable plastics and fibre-based packaging to integrating energy-saving process equipment into their manufacturing lines. Further, the article takes a deep dive into how connected industry solutions can help reduce and optimize energy consumption.
Pharma 4.0 - Impact Of IIOT In Pharmaceutical Manufacturing
With the growing number of medical ailments across the globe, the pharmaceutical industry will undoubtedly become more important than ever in the near future. There is a paradigm shift from the mass production of drugs to offering more customized and specialized drugs to a smaller group of patients and this is greatly expected to improve the effectiveness of treatments.
Digitalization Influences The Pharmaceutical Industry
Industry 4.0 is all about creating seamless connectivity in between machines, processes, and people within and beyond manufacturing facilities to increase quality, productivity and profit by using the power of advanced data analytics.
Primary Desiccant Packaging - No Chance For Moisture And Odours In Pharmaceutical Packaging
While moisture in pharmaceutical packaging can have negative or even dangerous effects on its content, unpleasant odours are especially repellent to patients. Both can be systematically prevented using suitable adsorbents – provided the right aspects are taken into account.
Staying Compliant And Profitable In The Pharmaceutical Packaging Process With Checkweighing
This article highlights use of checkweighing technology in pharma packaging and how it can help manufacturers improve their productivity through lowering changeover downtime and greater traceability.
B&R Celebrates 20 Years Of Growth & Innovation With Customers
To mark a glorious milestone of 20 years in India, B&R Industrial Automation, recently organised ‘CEO summit 2018’, which bought together CEOs from leading companies in machine building for an evening of business presentations, talk from renowned leadership speaker and candid conversations.
Powder Dryer End-point Detection For Aqueous & Solvent-based Drying
AMETEK Process Instruments offers powder manufacturers across a variety of industries a system for continuous, real-time monitoring and control of the powder drying process, whether it is aqueous- or solvent-based.
Novel Research In Pharmaceuticals And Bio-Pharmaceuticals
This article covers entire spectra of pharmaceutical research and as well as those related to synthesis and processing of pharmaceuticals.
